8.70

0.23% 0.02

After Hours: 8.70

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $8.70, with a volume of 1.56M. It is up +0.23% in the last 24 hours and down -1.36% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$8.68

Open:

$8.68

24h Volume:

1.56M

Relative Volume:

1.21

Market Cap:

$1.36B

Revenue:

$58.44M

Net Income/Loss:

$-80.74M

P/E Ratio:

-7.25

EPS:

-1.2

Net Cash Flow:

$-76.32M

1W Performance:

+2.84%

1M Performance:

-1.36%

6M Performance:

-4.40%

1Y Performance:

+177.07%

1-Day Range:

$8.63

$8.94

1-Week Range:

$8.44

$9.13

52-Week Range:

$1.995

$11.31

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

267

Twitter

@OCUTX

Next Earnings Date

2024-08-06

Latest SEC Filings

OCUL's Discussions on Twitter

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

08:51 AM

Ocular Therapeutix's SWOT analysis: stock poised for growth amid retina focus shift - Investing.com

08:51 AM

08:11 AM

Ocular Therapeutix's SWOT analysis: stock poised for growth amid retina focus shift - Investing.com India

08:11 AM

07:25 AM

Second Line Capital LLC Buys New Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

07:25 AM

Sep 25, 2024

Ocular Drug Delivery Global Market Advancements Highlighted by Size, Share, Trends, Forecast to 2033 - WhaTech

Sep 25, 2024

Ocular Therapeutix™ to Present at the UBS Virtual Ophthalmology Day 2024 - GlobeNewswire

Sep 25, 2024

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024 - Yahoo Finance

Sep 25, 2024

Sep 24, 2024

(OCUL) Trading Advice - Stock Traders Daily

Sep 24, 2024

Innovative eyewear insider acquires shares worth $997,895, sells for $490,400 - Investing.com Australia

Sep 24, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Logos Global Management LP's 9th Largest Position - MarketBeat

Sep 24, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Logos Global Management LP - MarketBeat

Sep 24, 2024

Otovo AS Rewards Loyalty with Share Program - TipRanks

Sep 24, 2024

Sep 23, 2024

Tri Locum Partners LP Buys Shares of 514,642 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Sep 23, 2024

UBS sees Domino's Pizza stock comeback on improved consumer outlook By Investing.com - Investing.com Australia

Sep 23, 2024

Sep 22, 2024

Rhumbline Advisers Has $1.45 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Sep 22, 2024

DekaBank Deutsche Girozentrale Invests $41,000 in OneSpan Inc. (NASDAQ:OSPN) - Defense World

Sep 22, 2024

Sep 21, 2024

Oppenheimer Asset Management Inc. Buys 7,385 Shares of Doximity, Inc. (NASDAQ:DOCS) - Defense World

Sep 21, 2024

Sep 20, 2024

Shareholders have faith in loss-making Ocular Therapeutix (NASDAQ:OCUL) as stock climbs 3.8% in past week, taking one-year gain to 177% - Simply Wall St

Sep 20, 2024

Sep 18, 2024

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $8.76 - MarketBeat

Sep 18, 2024